Free Trial

MAIA Biotechnology Q2 2024 Earnings Report

MAIA Biotechnology logo
$1.85 -0.05 (-2.63%)
As of 02/21/2025 04:10 PM Eastern

MAIA Biotechnology EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

MAIA Biotechnology Earnings Headlines

Maia Biotechnology Inc trading resumes
MAIA Biotechnology to sell 1.81M shares at $1.50 in private placement
Why Buffett and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Maia Biotechnology Inc trading halted, news pending
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA), a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

View MAIA Biotechnology Profile

More Earnings Resources from MarketBeat